Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681470 · ClinicalTrials.gov registry record · Phase 4
Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color
A Phase 4 study of Acne Vulgaris, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03681470 is a Phase 4 study of Acne Vulgaris that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 20 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03681470, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Acne vulgaris is a common skin disease characterized by inflammatory papules, pustules, and comedones that is prevalent in men and women of color. Research has demonstrated that Aczone ® (dapsone) gel, 7.5% used once daily is effective, safe, and well-tolerated for the treatment of acne in both men and women; however, limited data is available regarding its efficacy and safety in skin of color (SOC). The current study aims to investigate the therapeutic impact of Aczone gel 7.5% in SOC males and females ages 18 and older with acne vulgaris. The study will also evaluate the impact of Aczone ® gel on hyperpigmentation and PIH of the face.
Conditions Studied
Interventions
- DRUG Aczone Gel
Study Locations (1)
New York
- Mount Sinai West - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-04-09 |
| Est. Completion | 2021-05-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03681470
The ClinicalTrials.gov registry entry for NCT03681470 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (93% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Aczone Gel is the first listed.
NCT03681470 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03681470 about?
NCT03681470 is a clinical study titled "Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color". Acne vulgaris is a common skin disease characterized by inflammatory papules, pustules, and comedones that is prevalent in men and women of color. Research has demonstrated that Aczone ® (dapsone) gel, 7.5% used once daily is effective, safe, and well-tolerated for the treatment of acne in both men ...
What is the current status of trial NCT03681470?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2019-04-09. Estimated completion is 2021-05-06.
What conditions does trial NCT03681470 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT03681470?
The interventions under investigation include: Aczone Gel (DRUG).
Who is sponsoring clinical trial NCT03681470?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03681470 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
ACTIVE NOT RECRUITING · Phase 4
-
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 4
-
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
COMPLETED · Phase 4
-
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
COMPLETED · Phase 4
-
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
COMPLETED · Phase 4
-
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.